| Year |
Citation |
Score |
| 2024 |
Myers RM, Devine KJ, Li Y, Lawrence S, Barz Leahy A, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Wertheim G, Kulikovskaya I, Gonzalez V, Fraietta JA, ... ... Maude SL, et al. Reinfusion of CD19 CAR T Cells for Relapse Prevention and Treatment in Children with Acute Lymphoblastic Leukemia. Blood Advances. PMID 38386999 DOI: 10.1182/bloodadvances.2024012885 |
0.444 |
|
| 2023 |
Winestone LE, Bhojwani D, Ghorashian S, Muffly L, Leahy AB, Chao K, Steineck A, Rossig C, Lamble A, Maude SL, Myers R, Rheingold SR. INSPIRED Symposium Part 4A: Access to CAR T Cell Therapy in Unique Populations with B Cell Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. PMID 37821078 DOI: 10.1016/j.jtct.2023.10.005 |
0.429 |
|
| 2023 |
Lamble AJ, Moskop A, Pulsipher MA, Maude SL, Summers C, Annesley C, Baruchel A, Gore L, Amrolia P, Shah N. INSPIRED Symposium Part 2: Prevention and Management of Relapse Following CAR T-cell therapy for B-ALL. Transplantation and Cellular Therapy. PMID 37689393 DOI: 10.1016/j.jtct.2023.08.030 |
0.408 |
|
| 2023 |
McClory SE, Maude SL. The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America. PMID 37500380 DOI: 10.1016/j.hoc.2023.06.003 |
0.426 |
|
| 2023 |
Schultz L, Jacoby E, Lamble AJ, Maude SL, McNerney KO, Moskop A, Myers RM, Pulsipher MA, Shah NN. Introduction to the Reports from the Insights in Pediatric CAR T-cell Immunotherapy: Recent Advances and Future Directions (INSPIRED) Symposium. Transplantation and Cellular Therapy. PMID 37442348 DOI: 10.1016/j.jtct.2023.07.009 |
0.319 |
|
| 2023 |
Holland EM, Yates B, Steinberg SM, Yuan CM, Wang HW, Annesley C, Shalabi H, Stroncek D, Fry TJ, Krueger J, Jacoby E, Hsieh E, Bhojwani D, Gardner RA, Maude SL, et al. CAR T-cells as Salvage Therapy for post CAR T-cell Failure. Transplantation and Cellular Therapy. PMID 37394115 DOI: 10.1016/j.jtct.2023.06.019 |
0.347 |
|
| 2023 |
McNerney KO, Richards RM, Aguayo-Hiraldo P, Calkoen FG, Talano JA, Moskop A, Balduzzi A, Krajewski J, Dave H, Vatsayan A, Callahan C, Liu H, Li Y, Davis KL, Maude SL. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report. Journal For Immunotherapy of Cancer. 11. PMID 36707090 DOI: 10.1136/jitc-2022-005957 |
0.38 |
|
| 2022 |
Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, ... ... Maude SL, et al. Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy. Blood. PMID 36351239 DOI: 10.1182/blood.2022017866 |
0.39 |
|
| 2022 |
Diorio C, Vatsayan A, Talleur AC, Annesley C, Jaroscak JJ, Shalabi H, Ombrello AK, Hudspeth M, Maude SL, Gardner RA, Shah NN. Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. Blood Advances. PMID 35395068 DOI: 10.1182/bloodadvances.2022006983 |
0.324 |
|
| 2022 |
Amini L, Silbert SK, Maude SL, Nastoupil LJ, Ramos CA, Brentjens RJ, Sauter CS, Shah NN, Abou-El-Enein M. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nature Reviews. Clinical Oncology. PMID 35318469 DOI: 10.1038/s41571-022-00607-3 |
0.418 |
|
| 2022 |
Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine. PMID 35314843 DOI: 10.1038/s41591-022-01726-1 |
0.37 |
|
| 2022 |
Brivio E, Baruchel A, Beishuizen A, Bourquin JP, Brown PA, Cooper T, Gore L, Kolb EA, Locatelli F, Maude SL, Mussai FJ, Vormoor-Bürger B, Vormoor J, von Stackelberg A, Zwaan CM. Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma. European Journal of Cancer (Oxford, England : 1990). 164: 1-17. PMID 35121370 DOI: 10.1016/j.ejca.2021.12.029 |
0.365 |
|
| 2022 |
Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, Boyer MW, Hiramatsu H, Yanik GA, Driscoll T, Myers GD, Bader P, Baruchel A, Buechner J, Stefanski HE, et al. Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia. Blood Cancer Discovery. 3: 66-81. PMID 35019853 DOI: 10.1158/2643-3230.BCD-21-0095 |
0.347 |
|
| 2022 |
McNerney KO, DiNofia AM, Teachey DT, Grupp SA, Maude SL. Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. Blood Cancer Discovery. 3: 90-94. PMID 35015687 DOI: 10.1158/2643-3230.BCD-21-0203 |
0.412 |
|
| 2021 |
Barz Leahy A, Devine KJ, Li Y, Liu H, Myers RM, DiNofia A, Wray L, Rheingold SR, Callahan C, Baniewicz D, Patino M, Newman H, Hunger SP, Grupp SA, Barrett DM, ... Maude SL, et al. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T cell therapy. Blood. PMID 34871373 DOI: 10.1182/blood.2021012727 |
0.321 |
|
| 2021 |
Pearson AD, Rossig C, Mackall C, Shah NN, Baruchel A, Reaman G, Ricafort R, Heenen D, Bassan A, Berntgen M, Bird N, Bleickardt E, Bouchkouj N, Bross P, Brownstein C, ... ... Maude S, et al. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. European Journal of Cancer (Oxford, England : 1990). PMID 34840026 DOI: 10.1016/j.ejca.2021.10.016 |
0.467 |
|
| 2021 |
Leahy AB, Newman H, Li Y, Liu H, Myers R, DiNofia A, Dolan JG, Callahan C, Baniewicz D, Devine K, Wray L, Aplenc R, June CH, Grupp SA, Rheingold SR, ... Maude SL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. The Lancet. Haematology. 8: e711-e722. PMID 34560014 DOI: 10.1016/S2352-3026(21)00238-6 |
0.466 |
|
| 2021 |
Levine JE, Grupp SA, Pulsipher MA, Dietz AC, Rives S, Myers GD, August KJ, Verneris MR, Buechner J, Laetsch TW, Bittencourt H, Baruchel A, Boyer MW, De Moerloose B, Qayed M, ... ... Maude SL, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia. Journal For Immunotherapy of Cancer. 9. PMID 34353848 DOI: 10.1136/jitc-2020-002287 |
0.381 |
|
| 2021 |
Myers RM, Li Y, Barz Leahy A, Barrett DM, Teachey DT, Callahan C, Fasano CC, Rheingold SR, DiNofia A, Wray L, Aplenc R, Baniewicz D, Liu H, Shaw PA, Pequignot E, ... ... Maude SL, et al. Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003458. PMID 34156874 DOI: 10.1200/JCO.20.03458 |
0.445 |
|
| 2021 |
Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, Shyu A, Highfill SL, Price A, Zhao L, Peng L, ... ... Maude SL, et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nature Medicine. PMID 33888899 DOI: 10.1038/s41591-021-01326-5 |
0.4 |
|
| 2021 |
Faude S, Wei J, Muralidharan K, Xu X, Wertheim G, Paessler M, Bhoj VG, Grupp SA, Maude SL, Rheingold SR, Pillai V. Absolute lymphocyte count proliferation kinetics after CAR T-cell infusion impact response and relapse. Blood Advances. 5: 2128-2136. PMID 33881465 DOI: 10.1182/bloodadvances.2020004038 |
0.45 |
|
| 2021 |
Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, Gladney W, Lacey SF, Liu H, Maude SL, McGuire R, et al. Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002477. PMID 33417474 DOI: 10.1200/JCO.20.02477 |
0.364 |
|
| 2021 |
Lerman BJ, Li Y, Liu H, Myers RM, Devine K, Callahan C, Baniewicz D, Kadauke S, DiNofia AM, Rheingold SR, Wray L, Aplenc R, Grupp SA, Maude SL, Leahy AB. Complete Versus Incomplete Hematologic Recovery after CAR T Cell Therapy: Implications for Relapse Free Survival and Overall Survival in Pediatric and Young Adult Patients with Relapsed/Refractory B-ALL Blood. 138: 1747-1747. DOI: 10.1182/blood-2021-151114 |
0.417 |
|
| 2021 |
Myers RM, Devine K, Li Y, Lawrence S, Leahy AB, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Cameron MA, DiNofia AM, Rheingold SR, Aplenc R, ... ... Maude SL, et al. Outcomes after Reinfusion of CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Blood. 138: 474-474. DOI: 10.1182/blood-2021-147299 |
0.406 |
|
| 2021 |
Ghobadi A, Aldoss I, Locke FL, Mattison RJ, Bhojwani D, Maude SL, Dasgupta P, Mullis KG, Kabakibi A, Hamil AS, Leedom T, Chrobak K, McNulty E, Davidson-Moncada JK, Cooper ML, et al. A Phase 1/2 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL) Blood. 138: 4829-4829. DOI: 10.1182/blood-2021-146841 |
0.388 |
|
| 2020 |
Maus MV, Alexander S, Bishop MR, Brudno JN, Callahan C, Davila ML, Diamonte C, Dietrich J, Fitzgerald JC, Frigault MJ, Fry TJ, Holter-Chakrabarty JL, Komanduri KV, Lee DW, Locke FL, ... Maude SL, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal For Immunotherapy of Cancer. 8. PMID 33335028 DOI: 10.1136/jitc-2020-001511 |
0.318 |
|
| 2020 |
Diorio C, Maude SL. CAR T cells vs allogeneic HSCT for poor-risk ALL. Hematology. American Society of Hematology. Education Program. 2020: 501-507. PMID 33275706 DOI: 10.1182/hematology.2020000172 |
0.371 |
|
| 2020 |
Diorio C, Shaw PA, Pequignot E, Orlenko A, Chen F, Aplenc R, Barrett DM, Bassiri H, Behrens E, DiNofia AM, Gonzalez V, Koterba N, Levine BL, Maude SL, Meyer NJ, et al. Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Advances. 4: 5174-5183. PMID 33095872 DOI: 10.1182/bloodadvances.2020002592 |
0.337 |
|
| 2020 |
McNeer JL, Rau RE, Gupta S, Maude SL, O'Brien MM. Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 40: 1-12. PMID 32320280 DOI: 10.1200/EDBK_278171 |
0.354 |
|
| 2020 |
Singh N, Lee YG, Shestova O, Ravikumar P, Hayer KE, Hong SJ, Lu XM, Pajarillo R, Agarwal S, Kuramitsu S, Orlando EJ, Mueller KT, Good CR, Berger SL, Shalem O, ... ... Maude SL, et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T cell dysfunction. Cancer Discovery. PMID 32001516 DOI: 10.1158/2159-8290.Cd-19-0813 |
0.474 |
|
| 2020 |
Narayan V, Gladney W, Plesa G, Vapiwala N, Carpenter EL, Maude SL, Lal P, Lacey SF, Melenhorst JJ, Fraietta J, Sebro R, Farwell M, Moniak M, Gilmore J, Lledo L, et al. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 38: TPS269-TPS269. DOI: 10.1200/JCO.2020.38.6_SUPPL.TPS269 |
0.357 |
|
| 2020 |
Minard V, Maude SL, Buechner J, Krueger J, Locatelli F, Attarbaschi A, Laetsch TW, Martínez BG, Rubio CDdH, Awasthi R, Newsome S, Davis J, Bubuteishvili-Pacaud L, Burkhardt B. Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E22504 |
0.437 |
|
| 2020 |
Newman H, Leahy AEB, Li Y, Liu H, Myers RM, DiNofia AM, Dolan JG, Callahan C, Devine KJ, Wray L, June CH, Grupp SA, Rheingold SR, Maude SL. CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 38: 10511-10511. DOI: 10.1200/Jco.2020.38.15_Suppl.10511 |
0.499 |
|
| 2020 |
Myers RM, Fitzgerald JC, DiNofia A, Wray L, Leahy AB, Li Y, Smith LT, Burrows EK, Ramos M, Motley LS, Khan R, Aplenc R, Grupp SA, Maude SL. Inpatient and Intensive Care Unit Resource Utilization after CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy (CART19) for Pediatric Acute Lymphoblastic Leukemia (ALL) Biology of Blood and Marrow Transplantation. 26: S202-S203. DOI: 10.1016/J.Bbmt.2019.12.695 |
0.35 |
|
| 2020 |
Myers RM, Kadauke S, Li Y, Callahan CA, Gladney W, Fitzgerald JC, Wray L, Leahy AB, Baniewicz D, Motley LS, McGuire R, Shenoy V, Barrett DM, Teachey DT, Maude SL, et al. Risk-Adapted Preemptive Tocilizumab Decreases Severe Cytokine Release Syndrome (CRS) after CTL019 CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Biology of Blood and Marrow Transplantation. 26: S39. DOI: 10.1016/J.Bbmt.2019.12.105 |
0.402 |
|
| 2019 |
Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, Frey N, Gill SI, Grupp SA, Maude SL, Siegel DL, Levine BL, June CH, Lacey SF, Melenhorst JJ, et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. The Journal of Clinical Investigation. PMID 31845905 DOI: 10.1172/Jci130144 |
0.454 |
|
| 2019 |
Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, et al. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901892. PMID 31815579 DOI: 10.1200/Jco.19.01892 |
0.485 |
|
| 2019 |
Arnold DE, Maude SL, Callahan CA, DiNofia AM, Grupp SA, Heimall JR. Subcutaneous immunoglobulin replacement following CD19-specific chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukemia in pediatric patients. Pediatric Blood & Cancer. e28092. PMID 31793170 DOI: 10.1002/pbc.28092 |
0.358 |
|
| 2019 |
Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, ... ... Maude SL, et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Advances. 3: 3539-3549. PMID 31738832 DOI: 10.1182/Bloodadvances.2019000692 |
0.409 |
|
| 2019 |
DiNofia AM, Maude SL. Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL. Hemasphere. 3: e279. PMID 31723849 DOI: 10.1097/HS9.0000000000000279 |
0.463 |
|
| 2019 |
Chong EA, Levine BL, Grupp SA, Davis MM, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, Hwang WT, Chong ER, June CH, Schuster SJ. CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood. PMID 31554634 DOI: 10.1182/Blood.2019002258 |
0.358 |
|
| 2019 |
Meyer LK, Delgado-Martin C, Maude SL, Shannon KM, Teachey DT, Hermiston ML. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. Plos One. 14: e0220026. PMID 31318944 DOI: 10.1371/Journal.Pone.0220026 |
0.373 |
|
| 2019 |
Narayan V, Gladney W, Plesa G, Vapiwala N, Carpenter E, Maude SL, Lal P, Lacey SF, Melenhorst JJ, Sebro R, Farwell M, Hwang W, Moniak M, Gilmore J, Lledo L, et al. A phase I clinical trial of PSMA-directed/TGFβ-insensitive CAR-T cells in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 37: TPS347-TPS347. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps269 |
0.472 |
|
| 2019 |
Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Shyu A, Highfill S, Zhao L, Peng L, Granda B, Ramones M, Lu XM, Christian DA, Perazzelli J, ... ... Maude SL, et al. Single Chain Variable Fragment Linker Length Regulates CAR Biology and T Cell Efficacy Blood. 134: 247-247. DOI: 10.1182/Blood-2019-131024 |
0.494 |
|
| 2019 |
Barz Leahy A, Stanley KJ, Myers RM, DiNofia AM, Wray L, Rheingold SR, Callahan C, Baniewicz D, Barry AE, Patino MM, Hunger SP, Grupp S, Barrett DM, Maude SL. Cytogenetic Characteristics and Outcomes of Patients Receiving CTL019 CAR T Cell Therapy Blood. 134: 1464-1464. DOI: 10.1182/blood-2019-130060 |
0.315 |
|
| 2019 |
Wang M, Pruteanu I, Cohen AD, Garfall AL, Milone MC, Tian L, Gonzalez VE, Gill S, Frey NV, Barrett DM, Ruella M, Lacey SF, Svoboda J, Chong EA, Fraietta JA, ... ... Maude SL, et al. Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors Blood. 134: 622-622. DOI: 10.1182/Blood-2019-122513 |
0.438 |
|
| 2019 |
Awasthi R, Mueller KT, Yanik GA, Tam CS, Rives S, McGuirk JP, Pulsipher MA, Boyer MW, Jaeger U, Baruchel A, Myers GD, Borchmann P, Schuster SJ, Stefanski H, Bishop M, ... ... Maude SL, et al. Abstract CT237: Evaluation of in vivo chimeric antigen receptor (CAR) transgene levels in patients (pts) treated with tisagenlecleucel Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct237 |
0.388 |
|
| 2019 |
Kadauke S, Maude S, Gladney W, Motley L, Shenoy V, Callahan C, Baniewicz D, Teachey D, Grupp S, DiNofia A. Early administration of tocilizumab (Toci) for the prevention of grade 4 cytokine release syndrome (CRS) after CD19-directed CAR T-cell therapy (CTL019) Cytotherapy. 21: e2-e3. DOI: 10.1016/J.Jcyt.2019.04.009 |
0.453 |
|
| 2019 |
Chong E, Schuster S, Grupp S, Davis M, Siegel D, Maude S, Gladney W, Frey N, Porter D, June C, Levine B. Impact of CAR T-cell product viability on B-cell lymphoid malignancy outcomes Cytotherapy. 21: S19. DOI: 10.1016/J.Jcyt.2019.03.316 |
0.444 |
|
| 2019 |
Grupp SA, Maude SL, Rives S, Baruchel A, Boyer M, Bittencourt H, Bader P, Buchner J, Laetsch TW, Stefanski H, Myers GD, Qayed M, Pulsipher MA, Moerloose BD, Yanik GA, et al. Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia: Updated Analysis of the ELIANA Clinical Trial Biology of Blood and Marrow Transplantation. 25. DOI: 10.1016/J.Bbmt.2018.12.410 |
0.44 |
|
| 2019 |
Myers RM, Fitzgerald J, Elgarten CW, Getz KD, Li Y, Hogan J, Dinofia A, Burrows EK, Aplenc R, Grupp SA, Laskin B, Maude SL. Acute Kidney Injury after Chimeric Antigen Receptor T-Cell Therapy for Pediatric Acute Lymphoblastic Leukemia Biology of Blood and Marrow Transplantation. 25: S168-S169. DOI: 10.1016/J.Bbmt.2018.12.307 |
0.438 |
|
| 2019 |
Minard-Colin V, Burkhardt B, Maude S, Phillips C, Rubio CDdH, Laetsch TW, Curran K, Newsome S, Murray N, Pacaud L, Buechner J. Bianca: A Phase 2 Study Of The Safety And Efficacy Of Tisagenlecleucel In Pediatric Patients With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma Hematological Oncology. 37: 558-559. DOI: 10.1002/Hon.5_2632 |
0.379 |
|
| 2018 |
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, ... Maude SL, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nature Medicine. PMID 30275568 DOI: 10.1038/S41591-018-0201-9 |
0.502 |
|
| 2018 |
Mueller KT, Waldron ER, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August K, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, ... ... Maude SL, et al. Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30190371 DOI: 10.1158/1078-0432.Ccr-18-0758 |
0.492 |
|
| 2018 |
Gofshteyn JS, Shaw PA, Teachey DT, Grupp S, Maude S, Banwell B, Chen F, Lacey SF, Melenhorst JJ, Edmonson MJ, Panzer J, Barrett DM, McGuire J. Neurotoxicity after CTL019 in a Pediatric and Young Adult Cohort. Annals of Neurology. PMID 30178481 DOI: 10.1002/Ana.25315 |
0.317 |
|
| 2018 |
Leahy AB, Elgarten CW, Grupp SA, Maude SL, Teachey DT. Tisagenlecleucel for the treatment of B cell acute lymphoblastic leukemia. Expert Review of Anticancer Therapy. PMID 30111196 DOI: 10.1080/14737140.2018.1512411 |
0.461 |
|
| 2018 |
Burstein D, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac Profile of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Children: a Single Institution Experience. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29772353 DOI: 10.1016/J.Bbmt.2018.05.014 |
0.51 |
|
| 2018 |
Laetsch TW, Maude SL, Milone MC, Davis KL, Krueger J, Cardenas AM, Eldjerou LK, Keir CH, Wood PA, Grupp SA. False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods. Blood. PMID 29669777 DOI: 10.1182/Blood-2017-12-822940 |
0.423 |
|
| 2018 |
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. The New England Journal of Medicine. 378: 439-448. PMID 29385370 DOI: 10.1056/Nejmoa1709866 |
0.477 |
|
| 2018 |
Bride KL, Vincent TL, Im SY, Aplenc R, Barrett DM, Carroll WL, Carson R, Dai Y, Devidas M, Dunsmore KP, Fuller T, Glisovic-Aplenc T, Horton TM, Hunger SP, Loh ML, ... Maude SL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL). Blood. PMID 29305553 DOI: 10.1182/Blood-2017-07-794214 |
0.514 |
|
| 2018 |
Pillai V, Rosenthal J, Muralidharan K, Wertheim GB, Paessler M, Maude SL, Rheingold SR, Grupp SA. Correlation of pre-CAR CD19 expression with responses and relapses after CAR T cell therapy. Journal of Clinical Oncology. 36: 3051-3051. DOI: 10.1200/Jco.2018.36.15_Suppl.3051 |
0.518 |
|
| 2018 |
Mueller KT, Grupp SA, Maude SL, Levine JE, Pulsipher M, Boyer MW, August KJ, Myers GD, Awasthi R, Waldron EK, Bubuteishvili-Pacaud L, Taran T, Cota M, Tam CSL, Jäger U, et al. Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients. Journal of Clinical Oncology. 36: 3044-3044. DOI: 10.1200/Jco.2018.36.15_Suppl.3044 |
0.441 |
|
| 2018 |
Awasthi R, Mueller KT, Yanik GA, Tam CS, Rives S, McGuirk JP, Pulsipher MA, Boyer MW, Jaeger U, Baruchel A, Myers GD, Balke-Want H, Schuster SJ, Stefanski H, Bishop MR, ... ... Maude SL, et al. Evaluation of In Vivo CAR Transgene Levels in Relapsed/Refractory Pediatric and Young Adult ALL and Adult DLBCL Tisagenlecleucel-Treated Patients Blood. 132: 899-899. DOI: 10.1182/Blood-2018-99-116385 |
0.362 |
|
| 2018 |
Gupta S, Alexander S, Zupanec S, Athale U, Bassal M, Edwards E, Gibson PJ, Johnston D, Marjerrison S, Zorzi A, Hitzler JK, Naqvi A, Punnett A, Whitlock JA, Grupp SA, ... Maude SL, et al. High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada Blood. 132: 1410-1410. DOI: 10.1182/Blood-2018-99-115593 |
0.442 |
|
| 2018 |
Grupp SA, Maude SL, Rives S, Baruchel A, Boyer MW, Bittencourt H, Bader P, Büchner J, Laetsch TW, Stefanski H, Myers GD, Qayed M, Pulsipher MA, Moerloose BD, Yanik GA, et al. Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia Blood. 132: 895-895. DOI: 10.1182/Blood-2018-99-112599 |
0.48 |
|
| 2018 |
Li AM, Hucks GE, Dinofia AM, Seif AE, Teachey DT, Baniewicz D, Callahan C, Fasano C, McBride B, Gonzalez V, Nazimuddin F, Porter DL, Lacey SF, June CH, Grupp SA, ... Maude SL, et al. Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia Blood. 132: 556-556. DOI: 10.1182/Blood-2018-99-112572 |
0.451 |
|
| 2018 |
Chong EA, Levine BL, Grupp SA, Davis M, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, June CH, Schuster SJ. CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia Blood. 132: 197-197. DOI: 10.1182/Blood-2018-197 |
0.478 |
|
| 2018 |
Maya C, Barrera C, Srinivasan A, Vatsky S, Acord M, Escobar F, Grupp S, Maude S, Kim H, Cahill A. 3:45 PM Abstract No. 196 Nontunneled central apheresis catheter placement for T-cell harvesting in chimeric antigen receptor therapy: 5-year experience at a pediatric institution Journal of Vascular and Interventional Radiology. 29: S86. DOI: 10.1016/j.jvir.2018.01.220 |
0.314 |
|
| 2018 |
Arnold DE, Callahan CA, Maude SL, Grupp SA, Heimall J. Subcutaneous Immunoglobulin Replacement Following CD19-Specific Chimeric Antigen Receptor-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia Biology of Blood and Marrow Transplantation. 24: S171-S172. DOI: 10.1016/J.BBMT.2017.12.103 |
0.422 |
|
| 2017 |
Foster JB, Maude SL. New developments in immunotherapy for pediatric leukemia. Current Opinion in Pediatrics. PMID 29176353 DOI: 10.1097/Mop.0000000000000572 |
0.426 |
|
| 2017 |
Maude SL. CAR emissions: cytokines tell the story. Blood. 130: 2238-2240. PMID 29170192 DOI: 10.1182/Blood-2017-10-808592 |
0.419 |
|
| 2017 |
Mueller KT, Maude SL, Porter DL, Frey N, Wood P, Han X, Waldron E, Chakraborty A, Awasthi R, Levine BL, Melenhorst JJ, Grupp SA, June CH, Lacey SF. Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood. PMID 28935694 DOI: 10.1182/Blood-2017-06-786129 |
0.488 |
|
| 2017 |
Orlando E, Leary R, Lacey SF, Fraietta J, Bedoya F, Ambrose D, Wilcox N, Maude SL, Frey NV, Levine BL, Grupp SA, Porter DL, Young R, Winckler W, Morrissey M, et al. Gene expression signatures of response to anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with CLL and ALL. Journal of Clinical Oncology. 35: 137-137. DOI: 10.1200/Jco.2017.35.7_Suppl.137 |
0.523 |
|
| 2017 |
Burstein DS, Maude SL, Grupp SA, Griffis H, Rossano JW, Lin KY. Cardiac effects of chimeric antigen receptor (CAR) T-cell therapy in children. Journal of Clinical Oncology. 35: 10531-10531. DOI: 10.1200/Jco.2017.35.15_Suppl.10531 |
0.515 |
|
| 2017 |
Talekar MK, Maude SL, Hucks GE, Motley LS, Callahan C, White CM, Baniewicz D, Barrett DM, Rheingold SR, Lacey SF, Levine BL, Melenhorst JJ, Teachey DT, June CH, Grupp SA. Effect of chimeric antigen receptor-modified T (CAR-T) cells on responses in children with non-CNS extramedullary relapse of CD19+ acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 35: 10507-10507. DOI: 10.1200/Jco.2017.35.15_Suppl.10507 |
0.491 |
|
| 2017 |
Maude SL, Hucks GE, Seif AE, Talekar MK, Teachey DT, Baniewicz D, Callahan C, Gonzalez V, Nazimuddin F, Gupta M, Frey NV, Porter DL, Levine BL, Melenhorst JJ, Lacey SF, et al. The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 35: 103-103. DOI: 10.1200/Jco.2017.35.15_Suppl.103 |
0.512 |
|
| 2017 |
Ruella M, Maude SL, Engels B, Barrett DM, Frey N, Marcucci KT, Shestova O, Singh N, Perazzelli J, Christian DA, Haagen D, Lacey SF, Melenhorst JJ, Brogdon J, Young RM, et al. Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models Blood. 130: 807-807. DOI: 10.1182/Blood.V130.Suppl_1.807.807 |
0.551 |
|
| 2017 |
Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, June CH, Tomassian L, Shah S, Leung M, Huang P, Jolivet S, Awasthi R, ... ... Maude SL, et al. CTL019 Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor (CAR) T Cells to Characterize the Impact of Tocilizumab on Expansion and to Identify Correlates of Cytokine Release Syndrome Severity Blood. 130: 2561-2561. DOI: 10.1182/Blood.V130.Suppl_1.2561.2561 |
0.504 |
|
| 2017 |
Lee C, Bittencourt H, Rives S, Boyer MW, Pulsipher MA, Verneris MR, Yanik G, Jaitner B, Yi L, Lund K, Leung M, Awasthi R, Wood PA, Maude SL, Grupp SA, et al. Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019 Blood. 130: 2553-2553. DOI: 10.1182/Blood.V130.Suppl_1.2553.2553 |
0.458 |
|
| 2017 |
Maude SL, Hucks GE, Callahan C, Baniewicz D, Fasano C, Barker C, Rheingold SR, Aplenc R, Dinofia AM, Li A, Teachey DT, Barrett DM, Brogdon J, Young RM, Scholler J, et al. Durable Remissions with Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in CAR-Naive and CAR-Exposed Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Blood. 130: 1319-1319. DOI: 10.1182/Blood.V130.Suppl_1.1319.1319 |
0.523 |
|
| 2017 |
Mueller KT, Waldron E, Sickert D, Grupp SA, Maude SL, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Awasthi R, Levine BL, June CH, Taran T, Wood PA, et al. Impact of Humoral Immunogenicity (Anti-mCAR19 Antibodies) on CTL019 Cellular Kinetics, Efficacy, and Safety Blood. 130: 1281-1281. DOI: 10.1182/Blood.V130.Suppl_1.1281.1281 |
0.376 |
|
| 2017 |
Büchner J, Grupp SA, Maude SL, Hiramatsu H, Teachey DT, Wood PA, Awasthi R, Yi L, Moerloose BD. Management of Coagulopathy Associated with CTL019 CAR T-Cell Therapy Blood. 130: 1276-1276. DOI: 10.1182/Blood.V130.Suppl_1.1276.1276 |
0.401 |
|
| 2017 |
Bride KL, Vincent T, Im SL, Fuller T, Ryan T, Barrett DM, Maude SL, Loh ML, Hermiston ML, Grupp SA, Wood BL, Teachey DT. Abstract 2642: Preclinical efficacy of daratumumab in acute lymphoblastic leukemia Cancer Research. 77: 2642-2642. DOI: 10.1158/1538-7445.Am2017-2642 |
0.494 |
|
| 2017 |
Hucks G, Barrett D, Rheingold S, Aplenc R, Teachey D, Callahan C, Baniewicz D, White C, Talekar M, Shaw P, Brogdon J, Young R, Scholler J, Marcucci K, Chew A, ... ... Maude S, et al. Humanized chimeric antigen receptor (CAR)-modified T cells targeting CD19 induce remissions in children and young adults with relapsed/refractory lymphoblastic leukemia/lymphoma Cytotherapy. 19: S9-S10. DOI: 10.1016/J.Jcyt.2017.02.011 |
0.483 |
|
| 2017 |
Buechner J, Grupp SA, Maude SL, Boyer M, Bittencourt H, Laetsch TW, Bader P, Verneris MR, Stefanski H, Myers GD, Qayed M, Pulsipher MA, Moerloose BD, Hiramatsu H, Schlis K, et al. Global Registration Trial of Efficacy and Safety of CTL019 in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Update to the Interim Analysis Clinical Lymphoma, Myeloma & Leukemia. 17. DOI: 10.1016/J.Clml.2017.07.030 |
0.335 |
|
| 2017 |
Mueller KT, Waldron E, Grupp SA, Levine J, Laetsch TW, Pulsipher MA, Boyer M, August K, Hamilton J, Awasthi R, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, ... ... Maude S, et al. CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) Clinical Lymphoma Myeloma and Leukemia. 17: S261-S262. DOI: 10.1016/J.Clml.2017.07.028 |
0.319 |
|
| 2016 |
Maude SL. Future directions in chimeric antigen receptor T cell therapy. Current Opinion in Pediatrics. PMID 27841776 DOI: 10.1097/Mop.0000000000000436 |
0.449 |
|
| 2016 |
Yu H, Sotillo E, Harrington C, Wertheim G, Paessler M, Maude SL, Rheingold SR, Grupp SA, Thomas-Tikhonenko A, Pillai V. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. American Journal of Hematology. PMID 27779774 DOI: 10.1002/Ajh.24594 |
0.347 |
|
| 2016 |
Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Critical Care Medicine. PMID 27632680 DOI: 10.1097/Ccm.0000000000002053 |
0.441 |
|
| 2016 |
Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, Obstfeld AE, Lacey SF, Melenhorst JJ, Nazimuddin F, Hwang WT, Maude SL, Wasik MA, Bagg A, Schuster S, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T cell therapy. Blood. PMID 27166358 DOI: 10.1182/Blood-2016-01-694356 |
0.444 |
|
| 2016 |
Singh N, Frey NV, Grupp SA, Maude SL. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia. Current Treatment Options in Oncology. 17: 28. PMID 27098534 DOI: 10.1007/S11864-016-0406-4 |
0.524 |
|
| 2016 |
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, et al. Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery. PMID 27076371 DOI: 10.1158/2159-8290.Cd-16-0040 |
0.449 |
|
| 2016 |
Maude S, Barrett DM. Current status of chimeric antigen receptor therapy for haematological malignancies. British Journal of Haematology. 172: 11-22. PMID 26560054 DOI: 10.1111/Bjh.13792 |
0.512 |
|
| 2016 |
Frey NV, Shaw PA, Hexner EO, Gill S, Marcucci K, Luger SM, Mangan JK, Grupp SA, Maude SL, Ericson S, Levine B, Lacey SF, Melenhorst JJ, June CH, Porter DL. Optimizing chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 34: 7002-7002. DOI: 10.1200/Jco.2016.34.15_Suppl.7002 |
0.476 |
|
| 2016 |
Maude SL, Teachey DT, Rheingold SR, Shaw PA, Aplenc R, Barrett DM, Barker CS, Callahan C, Frey NV, Nazimuddin F, Lacey SF, Zheng Z, Levine B, Melenhorst JJ, Motley L, et al. Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL. Journal of Clinical Oncology. 34: 3011-3011. DOI: 10.1200/Jco.2016.34.15_Suppl.3011 |
0.522 |
|
| 2016 |
Maude SL, Barrett DM, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Shaw PA, Brogdon J, Young R, Scholler J, Marcucci K, Kulikovskaya I, Nazimuddin F, Zheng Z, Levine B, et al. Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL. Journal of Clinical Oncology. 34: 3007-3007. DOI: 10.1200/Jco.2016.34.15_Suppl.3007 |
0.492 |
|
| 2016 |
Meyer LK, Delgado-Martin C, Maude SL, Teachey DT, Hermiston ML. CRLF2 Rearrangement Status in Ph-like ALL Predicts Intrinsic Glucocorticoid Resistance In Vitro that is Reversible with Targeted MAPK and PI3K Pathway Inhibition Blood. 128: 910-910. DOI: 10.1182/Blood.V128.22.910.910 |
0.389 |
|
| 2016 |
Shalabi H, Qin H, Wanhainen K, Smith J, Orentas R, Shah NN, Maude SL, Tasian SK, Teachey DT, Khan J, Fry TJ. Preclinical Development of a T-Cell ALL CAR Demonstrates That Differences in CAR Membrane Distribution May Impact Efficacy Blood. 128: 4019-4019. DOI: 10.1182/Blood.V128.22.4019.4019 |
0.484 |
|
| 2016 |
Lacey SF, Shaw PA, Teachey DT, Weiss SL, Chen F, Gonzalez VE, Frey N, Porter DL, Maude SL, Grupp SA, Pequignot E, June CH, Melenhorst JJ. Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL) Blood. 128: 2812-2812. DOI: 10.1182/Blood.V128.22.2812.2812 |
0.415 |
|
| 2016 |
Lacey SF, Xu J, Ruella M, Barrett DM, Kulikovskaya I, Ambrose DE, Patel PR, Reich T, Scholler J, Nazimuddin F, Fraietta JA, Maude SL, Gill SI, Levine BL, Nobles CL, et al. Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR Blood. 128: 281-281. DOI: 10.1182/Blood.V128.22.281.281 |
0.487 |
|
| 2016 |
Maude SL, Pulsipher MA, Boyer MW, Grupp SA, Davies SM, Phillips CL, Verneris MR, August KJ, Schlis K, Driscoll TA, Mody R, Capitini CM, June CH, Levine BL, Wood PA, et al. Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis Blood. 128: 2801-2801. DOI: 10.1182/Blood.V128.22.2801.2801 |
0.477 |
|
| 2016 |
Grupp SA, Laetsch TW, Buechner J, Bittencourt H, Maude SL, Verneris MR, Myers GD, Boyer MW, Rives S, De Moerloose B, Nemecek ER, Schlis K, Martin PL, Qayed M, Bader P, et al. Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) Blood. 128: 221-221. DOI: 10.1182/Blood.V128.22.221.221 |
0.471 |
|
| 2016 |
Mueller KT, Chakraborty A, Wood PA, Awasthi R, Quintas-Cardama A, Han X, Maude SL, Grupp SA, Porter DL, Frey N, Marcucci KT, Levine BL, Melenhorst JJ, June CH, Lacey SF. Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia Blood. 128: 220-220. DOI: 10.1182/Blood.V128.22.220.220 |
0.498 |
|
| 2016 |
Maude SL, Barrett DM, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Baniewicz D, White C, Talekar MK, Shaw PA, Brogdon JL, Young RM, Scholler J, Marcucci KT, Levine BL, et al. Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Blood. 128: 217-217. DOI: 10.1182/Blood.V128.22.217.217 |
0.537 |
|
| 2016 |
Maude S, Barrett DM. Current status of chimeric antigen receptor therapy for haematological malignancies British Journal of Haematology. 172: 11-22. DOI: 10.1111/bjh.13792 |
0.424 |
|
| 2016 |
Levine B, Maude S, Zheng Z, Shaw P, Ambrose D, Aplenc R, Barker C, Barrett D, Brogdon J, Callahan C, Chen F, Chew A, Suhoski Davis M, Fesnak A, Finklestein J, et al. Durable Remissions with Control of Cytokine Release Syndrome (CRS) Using T Cells Expressing CD19 Targeted Chimeric Antigen Receptor (CAR) CTL019 to Treat Relapsed/Refractory (R/R) Acute Lymphoid Leukemia (ALL) Cytotherapy. 18: S14-S15. DOI: 10.1016/J.Jcyt.2016.03.039 |
0.47 |
|
| 2016 |
Singh N, Frey NV, Grupp SA, Maude SL. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia Current Treatment Options in Oncology. 17. DOI: 10.1007/s11864-016-0406-4 |
0.433 |
|
| 2015 |
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, ... Maude SL, et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discovery. PMID 26516065 DOI: 10.1158/2159-8290.Cd-15-1020 |
0.399 |
|
| 2015 |
Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, et al. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein. Blood. PMID 26041741 DOI: 10.1182/Blood-2014-11-612903 |
0.526 |
|
| 2015 |
Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 125: 4017-23. PMID 25999455 DOI: 10.1182/Blood-2014-12-580068 |
0.555 |
|
| 2015 |
Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hall J, Wood AC, Tasian SK, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 125: 1759-67. PMID 25645356 DOI: 10.1182/Blood-2014-06-580480 |
0.423 |
|
| 2015 |
Tasian SK, Li Y, Shen F, Ryan T, Vincent TL, Teachey DT, Maude SL, Harvey RC, Chen IL, Willman CL, Perl AE, Hunger SP, Loh ML, Carroll M, Grupp SA. Potent Efficacy of Combined PI3K/mTOR and JAK or SRC/ABL Inhibition in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia Blood. 126: 798-798. DOI: 10.1182/Blood.V126.23.798.798 |
0.322 |
|
| 2015 |
Maude SL, Barrett DM, Ambrose DE, Rheingold SR, Aplenc R, Teachey DT, Callahan C, Barker CS, Mudambi M, Shaw PA, Brogdon J, Young RM, Scholler J, Loew A, Marcucci KT, et al. Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL Blood. 126: 683-683. DOI: 10.1182/Blood.V126.23.683.683 |
0.523 |
|
| 2015 |
Grupp SA, Maude SL, Shaw PA, Aplenc R, Barrett DM, Callahan C, Lacey SF, Levine BL, Melenhorst JJ, Motley L, Rheingold SR, Teachey DT, Wood PA, Porter D, June CH. Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) Blood. 126: 681-681. DOI: 10.1182/Blood.V126.23.681.681 |
0.544 |
|
| 2015 |
Rheingold SR, Chen LN, Maude SL, Aplenc R, Barker C, Barrett DM, Callahan C, Cebry K, Kulikovskaya I, Lacey SF, Levine BL, Melenhorst JJ, Shaw PA, Sparrow A, Teachey DT, et al. Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL Blood. 126: 3769-3769. DOI: 10.1182/Blood.V126.23.3769.3769 |
0.448 |
|
| 2015 |
Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Frey NV, Maude SL, Barrett DM, Aplenc R, Chen F, Fitzgerald J, Gonzalez V, Pequignot E, Rheingold SR, Weiss S, White JC, et al. Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL) Blood. 126: 1334-1334. DOI: 10.1182/Blood.V126.23.1334.1334 |
0.476 |
|
| 2015 |
Sotillo E, Barrett D, Bagashev A, Black K, Lanauze C, Oldridge D, Sussman R, Harrington C, Chung EY, Hofmann TJ, Maude SL, Martinez NM, Raman P, Ruella M, Allman D, et al. Abstract 3143: Alternative splicing of CD19 mRNA in leukemias escaping CART-19 immunotherapy eliminates the cognate epitope and contributes to treatment failure Cancer Research. 75: 3143-3143. DOI: 10.1158/1538-7445.Am2015-3143 |
0.406 |
|
| 2014 |
Maude SL, Shpall EJ, Grupp SA. Chimeric antigen receptor T-cell therapy for ALL. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2014: 559-64. PMID 25696911 DOI: 10.1182/Asheducation-2014.1.559 |
0.54 |
|
| 2014 |
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. The New England Journal of Medicine. 371: 1507-17. PMID 25317870 DOI: 10.1056/Nejmoa1407222 |
0.524 |
|
| 2014 |
Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies Cancer Journal (United States). 20: 119-122. PMID 24667956 DOI: 10.1097/Ppo.0000000000000035 |
0.477 |
|
| 2014 |
Grupp SA, Maude SL, Shaw P, Aplenc R, Barrett DM, Callahan C, Chew A, Lacey SF, Levine BL, Melenhorst JJ, Motley L, Rheingold SR, Shen A, Teachey DT, Wood PA, et al. T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL Blood. 124: 380-380. DOI: 10.1182/Blood.V124.21.380.380 |
0.547 |
|
| 2014 |
Frey NV, Levine BL, Lacey SF, Grupp SA, Maude SL, Schuster SJ, Shaw P, Hwang W, Wasik MA, Obstfeld A, Leung M, Shen A, Ericson SG, Melenhorst JJ, June CH, et al. Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells Blood. 124: 2296-2296. DOI: 10.1182/Blood.V124.21.2296.2296 |
0.422 |
|
| 2014 |
Porter DL, Lacey SF, Hwang W, Shaw P, Frey NV, Chew A, Chen F, Kalos M, Gonzalez V, Marcucci KT, Maude SL, Melenhorst JJ, Litchman M, Teachey DT, Shen A, et al. Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL Blood. 124: 1983-1983. DOI: 10.1182/Blood.V124.21.1983.1983 |
0.406 |
|
| 2014 |
Grupp SA, Maude S, Aplenc R, Barrett DM, Kalos M, Levine B, Lichtman M, Rheingold S, Shen A, Strait C, Teachey D, Wood PA, June C. Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr06 |
0.552 |
|
| 2014 |
Maude SL, Dolai S, Delagdo-Martin C, Vincent T, Robbins A, Selvanathan A, Ryan T, Hunger SP, Loh ML, Mullighan CG, Wood BL, Hermiston ML, Grupp SA, Lock RB, Teachey DT. Abstract 997: Targeting the Jak/Stat signaling pathway is highly effective in xenograft models of early T cell precursor (ETP) acute lymphoblastic leukemia (ALL) Cancer Research. 74: 997-997. DOI: 10.1158/1538-7445.Am2014-997 |
0.399 |
|
| 2013 |
Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 121: 5154-7. PMID 23678006 DOI: 10.1182/Blood-2013-02-485623 |
0.513 |
|
| 2013 |
Grupp SA, Frey NV, Aplenc R, Barrett DM, Chew A, Kalos M, Levine BL, Litchman M, Maude SL, Rheingold SR, Shen A, Strait C, Teachey DT, Wood PA, Porter D, et al. T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL Blood. 122: 67-67. DOI: 10.1182/Blood.V122.21.67.67 |
0.557 |
|
| 2012 |
Maude SL, Tasian SK, Vincent T, Hall JW, Sheen C, Roberts KG, Seif AE, Barrett DM, Chen IM, Collins JR, Mullighan CG, Hunger SP, Harvey RC, Willman CL, Fridman JS, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 120: 3510-8. PMID 22955920 DOI: 10.1182/Blood-2012-03-415448 |
0.361 |
|
| 2012 |
Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, ... ... Maude SL, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 22: 153-66. PMID 22897847 DOI: 10.1016/J.Ccr.2012.06.005 |
0.35 |
|
| 2012 |
Tasian SK, Maude SL, Hall J, Vincent T, Mullighan CG, Willman CL, Hunger S, Loh ML, Teachey DT, Grupp SA. In vivo monitoring of JAK/STAT and PI3K/mTOR signal transduction inhibition in pediatric CRLF2-rearranged acute lymphoblastic leukemia (ALL). Journal of Clinical Oncology. 30: 9506-9506. DOI: 10.1200/Jco.2012.30.15_Suppl.9506 |
0.356 |
|
| 2011 |
Maude SL, Tasian SK, Vincent T, Hall JW, Collins-Underwood R, Mullighan CG, Hunger SP, Willman CL, Loh ML, Grupp SA, Teachey DT. Targeting mTOR and JAK2 in Xenograft Models of CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL) Blood. 118: 249-249. DOI: 10.1182/Blood.V118.21.249.249 |
0.423 |
|
| 2006 |
Enders GH, Maude SL. Traffic safety for the cell: influence of cyclin-dependent kinase activity on genomic stability. Gene. 371: 1-6. PMID 16458456 DOI: 10.1016/J.Gene.2005.11.017 |
0.651 |
|
| 2005 |
Maude SL, Enders GH. Cdk inhibition in human cells compromises chk1 function and activates a DNA damage response. Cancer Research. 65: 780-6. PMID 15705874 |
0.646 |
|
| Show low-probability matches. |